Loading…
TruBridge, Inc. provides healthcare solutions and services for community hospitals, clinics, and other healthcare systems in the United States and internationally. The company operates in two segments, Financial Health and Patient Care. It offers revenue cycle management (RCM) products, including patient liability estimate, eligibility verification, claim scrubbing and submission, remittance management, denial/audit management, and contract management services; RCM services, such as accounts receivable management, private pay service, medical coding, revenue cycle consulting, and other additional insurance and patient billing services; consulting, business intelligence, staffing, and administrative services; cloud services, backup and recovery, collaboration and connectivity, security services, systems management, and help desk services; and encoder solutions. The company also provides TruBridge HER, a software solution platform which offers various software applications using one fully integrated system designed to streamline the flow of information to the primary functional areas of community hospitals. In addition, it offers acute care support and maintenance services comprising total system support, national client conference, continuing education, software releases, hardware replacement, cloud electronic health record, forms and supplies, instantPHR, and CHBase. Further, the company provides business management services; acute care EHR solutions and related services for community hospitals, and their physician clinics; and patient engagement and technology solutions. The company was formerly known as Computer Programs and Systems, Inc. and changed its name to TruBridge, Inc. in March 2024. TruBridge, Inc. was founded in 1979 and is headquartered in Mobile, Alabama.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $347M | $42M | $4M | $20M | 2.4% | 1.4% | - |
| 2024 | $342M | $34M | $-21M | $13M | -12.5% | 1.6% | - |
| 2023 | $337M | $-19M | $-48M | $-22M | -26.2% | 3.2% | -403.4% |
| 2022 | $327M | $48M | $16M | $13M | 6.8% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 326.65 | 336.96 | 342.20 | 346.84 |
| Cost Of Revenue | 166.54 | 175.56 | 168.92 | 162.97 |
| Gross Profit | 160.11 | 161.40 | 173.28 | 183.86 |
| Operating Expense | 137.32 | 168.83 | 166.91 | 163.03 |
| Operating Income | 22.78 | -7.43 | 6.37 | 20.83 |
| EBITDA | 47.73 | -18.62 | 34.27 | 42.46 |
| EBIT | 24.40 | -44.94 | 5.70 | 16.18 |
| Pretax Income | 18.08 | -57.46 | -10.47 | 3.87 |
| Tax Provision | 2.21 | -9.33 | 10.48 | -0.48 |
| Net Income | 15.87 | -48.13 | -20.95 | 4.35 |
| Net Income Common Stockholders | 15.56 | -47.05 | -20.16 | 4.21 |
| Total Expenses | 303.87 | 344.40 | 335.83 | 326 |
| Interest Expense | 6.32 | 12.52 | 16.17 | 12.32 |
| Research And Development | 31.90 | 38.83 | 35.45 | 32.56 |
| Selling General And Administration | 82.10 | 103.68 | 102.90 | 104.20 |
| Normalized EBITDA | 47.73 | 19.64 | 34.27 | 42.46 |
| Normalized Income | 15.87 | -16 | -20.95 | 4.35 |
| Basic EPS | 1.08 | -3.15 | -1.55 | 0.29 |
| Diluted EPS | 1.08 | -3.15 | -1.55 | 0.29 |
| Tax Effect Of Unusual Items | 0 | -6.12 | 0 | 0 |
| Tax Rate For Calcs | 0.12 | 0.16 | 0.21 | 0.21 |
| Total Unusual Items | 0 | -38.26 | 0 | 0 |
| Total Unusual Items Excluding Goodwill | 0 | -38.26 | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | 15.87 | -48.13 | -20.95 | 4.35 |
| Reconciled Depreciation | 23.33 | 26.32 | 28.57 | 26.28 |
| Reconciled Cost Of Revenue | 166.54 | 175.56 | 168.92 | 162.97 |
| Net Interest Income | -6.32 | -12.52 | -16.17 | -12.32 |
| Net Income From Continuing And Discontinued Operation | 15.87 | -48.13 | -20.95 | 4.35 |
| Total Operating Income As Reported | 22.78 | -45.69 | 6.37 | 20.83 |
| Diluted Average Shares | 14.36 | 14.19 | 14.30 | 14.49 |
| Basic Average Shares | 14.36 | 14.19 | 14.30 | 14.49 |
| Diluted NI Availto Com Stockholders | 15.56 | -47.05 | -20.16 | 4.21 |
| Otherunder Preferred Stock Dividend | 0.31 | -1.08 | -0.79 | 0.14 |
| Net Income Including Noncontrolling Interests | 15.87 | -48.13 | -20.95 | 4.35 |
| Net Income Continuous Operations | 15.87 | -48.13 | -20.95 | 4.35 |
| Other Income Expense | 1.62 | -37.51 | -0.67 | -4.65 |
| Other Non Operating Income Expenses | 1.62 | 0.74 | -0.67 | -4.65 |
| Special Income Charges | 0 | -38.26 | 0 | 0 |
| Other Special Charges | 0.12 | 0 | 0 | 0 |
| Impairment Of Capital Assets | 0 | 38.26 | 0 | 0 |
| Restructuring And Mergern Acquisition | -0.56 | 0 | 0 | 0 |
| Net Non Operating Interest Income Expense | -6.32 | -12.52 | -16.17 | -12.32 |
| Interest Expense Non Operating | 6.32 | 12.52 | 16.17 | 12.32 |
| Depreciation Amortization Depletion Income Statement | 23.33 | 26.32 | 28.57 | 26.28 |
| Depreciation And Amortization In Income Statement | 23.33 | 26.32 | 28.57 | 26.28 |
| Amortization | 20.89 | 24.38 | 27.22 | 25.18 |
| Amortization Of Intangibles Income Statement | 20.89 | 24.38 | 27.22 | 25.18 |
| Depreciation Income Statement | 2.44 | 1.95 | 1.35 | 1.09 |
| Selling And Marketing Expense | 27.13 | 27.53 | 25.91 | 23.51 |
| General And Administrative Expense | 54.97 | 76.15 | 76.99 | 80.69 |
| Other Gand A | 54.97 | 76.15 | 76.99 | 80.69 |
| Operating Revenue | 326.65 | 336.96 | 342.20 | 346.84 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| TruBridge, Inc.this co. | TBRG | $386M | 88.72↑ premium | 2.10 | 2.4% | 13.37 |
| CTEV | CTEV | $391M | - | -2.19 | 170.1% | 9.33 |
| Weave Communications, Inc. | WEAV | $385M | - | 4.61 | -34.1% | -18.58 |
| Cerus Corporation | CERS | $385M | - | 5.75 | -24.1% | -52.90 |
| Niagen Bioscience, Inc. | NAGE | $381M | 23.80 |
| 4.97 |
| 22.7% |
| 21.23 |
| Puma Biotechnology, Inc. | PBYI | $381M | 12.26 | 2.89 | 23.9% | 6.57 |
| Viemed Healthcare, Inc. | VMD | $381M | 26.73 | 2.66 | 10.4% | 7.66 |
| Rocket Pharmaceuticals, Inc. | RCKT | $380M | - | 1.36 | -80.5% | -0.98 |
| OrthoPediatrics Corp. | KIDS | $376M | - | 1.06 | -11.4% | -53.45 |
| Peer Median | - | 23.80 | 2.77 | -0.5% | 2.79 | |